Message-based Outreach Intervention for Survivors for Carcinoma, Ovarian Epithelial
This study is evaluating whether a set of messages can help people learn about cancer genetics.
See full descriptionAbout the trial for Carcinoma, Ovarian Epithelial
Treatment Groups
This trial involves 4 different treatments. Message-based Outreach Intervention For Survivors is the primary treatment being studied. Participants will be divided into 2 treatment groups. There is no placebo group. The treatments being tested are not being studied for commercial purposes.
Eligibility
This trial is for patients born any sex aged 18 and older. There are 9 eligibility criteria to participate in this trial as listed below.
Approximate Timelines
Measurement Requirements
This trial is evaluating whether Message-based Outreach Intervention for Survivors will improve 4 primary outcomes and 7 secondary outcomes in patients with Carcinoma, Ovarian Epithelial. Measurement will happen over the course of Up to 31 months.
Who is running the study
Principal InvestigatorPatient Q & A Section
What is the primary cause of carcinoma, ovarian epithelial?
The overall frequency of the various causes of epithelial tumour of the ovary in this population was similar to those reported in the literature. Ovarian cancer is largely due to benign or pre-malignant conditions. Application of the International Federation of Gynecology and Obstetrics staging system does not provide any advantage over the existing FIGO staging system.
Have there been other clinical trials involving message-based outreach intervention for survivors?
Results from a recent clinical trial suggests that most clinical trials involve only one group of participants. Future clinical trials may need to include more participants to obtain better results. A systematic review of these studies could contribute to the development of future clinical trials.
What is the latest research for carcinoma, ovarian epithelial?
There was a significant increase regarding the number of new studies published on basic biology, cell biology, genetics, molecular biology, and immunology of carcinoma, ovarian epithelial tumors with respect to a decade ago.
What are common treatments for carcinoma, ovarian epithelial?
Data from a recent study of this review indicate that there are many possible patterns of cancer treatment combinations. These options vary significantly depending upon the staging and type of tumor.
How many people get carcinoma, ovarian epithelial a year in the United States?
Carcinoma, ovarian epithelial is rare in the U.S. population, with an incidence rate of about 0.1% per year. This low incidence may reflect a high prevalence of early detection of ovarian malignancy. However, cancer prevention strategies should target high-risk groups such as women with increased BRCA mutation carriership, women with a family history of breast and ovarian cancers, and women over 50 years old.
What is the survival rate for carcinoma, ovarian epithelial?
Survival rate for carcinoma, ovarian epithelial is only 26% at 5 years. The majority of cases of carcinoma, ovarian epithelial were stage III and stage IV at time of diagnosis. Survival rates were lower among patients < 45 years old, whose cancer was not resectable. To decrease the mortality rate for patients with this type of cancer, surgeons should strive to obtain complete surgical resection whenever possible.
How quickly does carcinoma, ovarian epithelial spread?
Carcinoma of the ovary spreads locally but rarely metastasizes. For early stage disease, the median time interval between diagnosis and death was 2.8 years (range 1.5-6.1 years). The 5 year survival rate was 25%.
What are the chances of developing carcinoma, ovarian epithelial?
The average age at diagnosis for carcinoma, ovarian epithelial was 45 yr, with a range of 31-50 yr. A significant percentage of patients were cleared of cancer after surgery (5%). A majority of cases were diagnosed as early stage (Ia and Ib) carcinoma, ovarian epithelial. A minority of patients had advanced disease at presentation (III and IV). OS was 63+/-11 months, with progressive disease being found in 5% of patients. More than half of all patients had experienced chemotherapy, with 2% receiving platinum-based chemotherapy alone.
Who should consider clinical trials for carcinoma, ovarian epithelial?
The authors conclude that there is no evidence that the risk of major side effects differs between early stage carcinoma and serous borderline tumors. Therefore, an argument against clinical trials can be made on ethical grounds only for early stage carcinomas. However, this remains controversial because of the relatively small number of patients included in trials.
Does message-based outreach intervention for survivors improve quality of life for those with carcinoma, ovarian epithelial?
Survivors who participated in the MOB program reported increased self-efficacy, fewer depressive symptoms, and better QoL. Data from a recent study highlight the need for an effective survivorship care model that addresses the emotional needs of survivorship patients.
Can carcinoma, ovarian epithelial be cured?
Findings from a recent study suggest that breast cancer cells may be sensitive to this combination chemotherapy regimen. Further investigation into whether this combination chemotherapy regimen will be effective against other tumors should be undertaken before recommending its use for breast cancer.